About Sirtex
Sirtex is a publicly listed company based in Sydney (Australia) founded in 1991, and was acquired by CDH in June 2018. Radiation therapy for cancer treatment is developed and provided. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Sirtex has completed 1 acquisition, including OncoSec Medical. Sirtex offers products and services including SIR-Spheres Y-90 Resin Microspheres, LAVA Liquid Embolic System, and SIROS INSYTE with SurePlan LiverY90. Its focus areas include Medical Devices and Oncology Devices. Its legal entity is Sirtex Medical Inc.
Company details
Sirtex is focused on the development and distribution of innovative medical devices for the treatment of liver cancer and related conditions. The company specializes in products like SIR-Spheres Y-90 Resin Microspheres for treating unresectable liver tumors and metastases, alongside other solutions such as the LAVA Liquid Embolic System for embolization procedures. Operating in the healthcare sector, Sirtex serves professionals and patients globally through offices in the United States, Australia, Germany, and Singapore. Their offerings are tailored to address critical needs in oncology, providing targeted therapies and support for complex medical challenges.
- Headquarters Sydney, Australia
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website sirtex.com/us
- Social LinkedIn X YouTube
- Acquired by CDH (Jun 2018)
- Legal Name Sirtex Medical Inc.
- Investors
- Investments & Acquisitions
- Acquired byCDH
(Jun 2018)
Products & Services of Sirtex
Sirtex offers a comprehensive portfolio of products and services, including SIR-Spheres Y-90 Resin Microspheres, LAVA Liquid Embolic System, and SIROS INSYTE with SurePlan LiverY90.
Used for treating unresectable liver tumors and metastases.
Designed for embolization in various medical treatment procedures.
Supports planning and delivery of liver cancer treatments.
Apps and channels of Sirtex
its YouTube channel Sirtex Medical US has 805 subscribers and 25 videos.
Videos from Sirtex
The most watched videos on Sirtex's YouTube channel, Sirtex Medical US (805 subscribers). Click a video to play it here.
More on Sirtex Medical US.
Investors in Sirtex
Sirtex has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include China Grand Pharmaceutical and Healthcare and CDH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and private debt firm focused on multiple sectors | cdhfund.com | Kowloon, China | ||
Finished formulations and APIs are manufactured for therapeutic categories. | 1995 | chinagrandpharm.com | Hong Kong, China |
Investor details for Sirtex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sirtex
80 people are tracked at Sirtex (34 in leadership, 46 in team).
| Name | Role | Group |
|---|---|---|
Jeffrey Cyr | Vice President Of Regulatory Affairs & Quality Assurance | Leadership |
Francis Jannot | Executive Vice President International Commercial | Leadership |
Antoine Lecourt | Senior Director Of EMEA Marketing | Leadership |
Catherine W. Parham | Chief Medical Officer & EVP of Research & Development | Leadership |
Bryan Sepulveda | Head Of Global Medical Affairs | Leadership |
Eugene Dinescu | Global MACA Head Of Operations, Finance, Strategy, And Pharmacovigilance | Leadership |
Matt Schmidt | Chief Executive Officer | Leadership |
Tom Bancroft | Vice President Operations | Leadership |
Scott Johnson | Area Sales Director - Southeastern U.s. | Leadership |
Mark Powell | Area Sales Director | Leadership |
Klay Thompson | Director Information Technology Operations | Leadership |
Michael von Poncet M.D. | Senior Vice President Medical & Clinical Affairs | Leadership |
Rick Kadile | Director Of Marketing, North America | Leadership |
Linda Teigland | Director, Business System Applications | Leadership |
Nathalie Amoury | Senior Director Health Economics & Market Access | Leadership |
Bergmann-Franke Brit | Human Resources Director | Leadership |
Sonnia Quintero Merwin | Sr. Director, Human Resources | Leadership |
Chandrahas Menon | Managing Director - India | Leadership |
John Grappo | Area Sales Director | Leadership |
Justin Watkins | Area Sales Director - Great Lakes | Leadership |
60 more people are available in the full profile.
Complete people profiles for Sirtex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sirtex
Sirtex has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include OncoSec Medical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Intratumoral immunotherapies are developed to harness immune responses against cancer. | oncosec.com | San Diego, United States | 2011 | Oct 2019 | $30M |
Complete acquisition details for Sirtex
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sirtex
4 dated milestones of Sirtex across 31 years, from founding to its latest funding, stage changes and deals.
- Founded Sirtex is founded.
- Exit Acquired by CDH.
- Acquisition Acquires OncoSec Medical.
- IPO Lists on the stock exchange (IPO).
Web traffic of Sirtex
The website of Sirtex (sirtex.com) receives about 8.7K visits a month.
- Monthly visits8.7K
▲ 51.5% vs previous month
Websites whose visitors overlap most with Sirtex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| covidien.com | 100% | View details | |||
| bms.com | 82% | 809.8K | #67,210 | View details | |
medical.siemens.com | medical.siemens.com | 82% | – | ||
| cordis.com | 75% | 44.3K | #735,879 | View details | |
| merit.com | 74% | 148.9K | #231,535 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Sirtex
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sirtex
Complete news archive for Sirtex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sirtex
Sirtex was founded in 1991.
Sirtex is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Sirtex is focused on the development and distribution of innovative medical devices for the treatment of liver cancer and related conditions. The company specializes in products like SIR-Spheres Y-90 Resin Microspheres for treating unresectable liver tumors and metastases, alongside other solutions such as the LAVA Liquid Embolic System for embolization procedures. Operating in the healthcare sector, Sirtex serves professionals and patients globally through offices in the United States, Australia, Germany, and Singapore. Their offerings are tailored to address critical needs in oncology, providing targeted therapies and support for complex medical challenges.
Sirtex offers SIR-Spheres Y-90 Resin Microspheres, LAVA Liquid Embolic System, and SIROS INSYTE with SurePlan LiverY90.
Sirtex has made 1 acquisition, including OncoSec Medical.
Sirtex has 2 investors. Key investors include China Grand Pharmaceutical and Healthcare, and CDH.
Sirtex operates through Sirtex Medical Inc..
Yes. Sirtex was acquired by CDH in June 2018.